CTOs on the Move

Scripps Translational Science Institute

www.stsiweb.org

 
The Scripps Translational Science Institute (STSI) at The Scripps Research Institute (TSRI) aims to replace the status-quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital technology for real-time health monitoring.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.stsiweb.org
  • 3344 North Torrey Pines Court Suite 300
    La Jolla, CA USA 92037
  • Phone: 858.784.2028

Executives

Name Title Contact Details

Funding

Scripps Translational Science Institute raised $34M on 05/02/2018

Similar Companies

Cyagen

Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!

Trisand Inc

Trisand Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.

MMI Genomics

MMI Genomics is a Davis, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synosia Therapeutics

Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.